Regeneron Pharmaceuticals, Inc. (BVMF:REGN34)
Brazil · Delayed Price · Currency is BRL | Market Cap | 349.62B -2.2% |
| Revenue (ttm) | 77.83B +5.9% |
| Net Income | 23.08B -1.7% |
| EPS | 214.20 +4.1% |
| Shares Out | n/a |
| PE Ratio | 15.15 |
| Forward PE | 12.34 |
| Dividend | 0.22 (0.36%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 1,237 |
| Average Volume | 781 |
| Open | 59.31 |
| Previous Close | 60.61 |
| Day's Range | 56.19 - 59.31 |
| 52-Week Range | 44.82 - 73.33 |
| Beta | 0.40 |
| RSI | 27.53 |
| Earnings Date | Apr 29, 2026 |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent ... [Read more]
Financial Performance
In 2025, Regeneron Pharmaceuticals's revenue was $14.34 billion, an increase of 0.99% compared to the previous year's $14.20 billion. Earnings were $4.50 billion, an increase of 2.09%.
Financial numbers in USD Financial StatementsNews
Regeneron Pharmaceuticals Analysts Cut Their Forecasts Following Q1 Earnings
Regeneron Pharmaceuticals (NASDAQ:REGN) on Wednesday reported better-than-expected first-quarter financial results and announced a $3 billion share buyback.
Regeneron Flags FDA Delays For Eylea HD Prefilled Syringe
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) on Wednesday reported first-quarter adjusted earnings of $9.47 per share, up 15% year-over-year, beating the consensus of $8.89.
Regeneron Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw 19% revenue growth and 15% EPS growth, driven by strong Dupixent, EYLEA HD, and Libtayo sales. Key pipeline advances, new collaborations, and a $3B share repurchase authorization position the company for continued momentum.
Regeneron beats quarterly results estimates on strong Dupixent demand
Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue on Wednesday, helped by strong demand for its eczema drug, Dupixent, and cancer drug, Libtayo, offsetting com...
Regeneron Reports First Quarter 2026 Financial and Operating Results
TARRYTOWN, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2026 and provided a business update.
Regeneron weighs overseas price for Otarmeni, gene therapy for rare type of hearing loss
Regeneron will make its newly approved gene therapy Otarmeni for a rare, genetic form of hearing loss available for free in the U.S. The company hasn't decided how it will price the therapy overseas, ...
Regeneron Strikes Deal With Trump Administration To Cut Drug Prices
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) has reached an agreement with the U.S. government to lower drug prices, expand patient access, and provide a newly approved gene therapy at no cost, aligni...
Regeneron CEO on deal with Trump admin to lower drug prices
Regeneron inked a deal with the Trump administration to lower drug prices and avoid planned tariffs. CEO Leonard Schleifer told CNBC's "Squawk Box" on Friday that "we have to support this industry," b...
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S.
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump. The biotech company will also offer the first hearing-loss gene therapy for free to eligibl...
Regeneron to offer prescriptions at most favored nation prices, Trump says
U.S. President Donald Trump said on Thursday that Regeneron has agreed to offer prescriptions at most favored nation prices.
FDA Approves First-Ever Gene Therapy to Restore Hearing
Regeneron's drug restored hearing in 11 of 12 children in a rare, inherited condition that causes deafness.
FDA approves Regeneron's gene therapy for inherited deafness
U.S. Food and Drug Administration has approved Regeneron's gene therapy for a rare genetic form of deafness, the company said on Thursday.
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting t...
White House to announce drug pricing deal with Regeneron, source says
The White House will announce a drug pricing deal with Regeneron Pharmaceuticals on Thursday, according to a source familiar with the matter.
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program
Press Release: Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Regeneron Pharmaceuticals Transcript: Status update
The C5 program utilizes a flexible siRNA and antibody approach to tailor complement inhibition for diseases like PNH, gMG, and Geographic Atrophy, showing strong efficacy and safety in late-stage trials. Commercial strategy targets multi-billion-dollar markets with differentiated dosing and administration advantages.
Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
Regeneron and Telix Announce Strategic Radiopharma Collaboration
Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)
Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduce...
Press Release: Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions
Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX's industry-leading global network of electronic health record data Collaboration will expand Re...